Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Seikagaku
Company Location: Asia Pacific
Company Founding Year: 1947
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dry Eye Syndromes|Keratoconjunctivitis Sicca|Dry Eye Disease
Phase 2: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05411367 |
SIDE | P3 |
Completed |
Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca |
2023-03-02 |
7% |
2026-01-17 |
Primary Endpoints |
NCT01558999 |
NCT01558999 | P2 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2012-07-01 |
2019-03-19 |
Treatments |
|
NCT02205840 |
NCT02205840 | P3 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2014-11-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|